Response to propranolol in infantile hemangioma

Area of Science:

• Pediatric Dermatology
• Vascular Biology

Background:

• Infantile hemangioma (IH) is a common pediatric vascular tumor.
• Propranolol is an established treatment for IH, but optimal dosing strategies are still explored.

Purpose of the Study:

• To evaluate the efficacy of a lower initial dose of propranolol (1 mg/kg/day) for infantile hemangioma.
• To determine the optimal titration strategy for propranolol treatment in infants with IH.

Main Methods:

• Sixteen infants with newly diagnosed IH received propranolol, starting at 0.5 mg/kg/day, then titrated to 1 or 2 mg/kg/day.
• Treatment continued until lesions achieved clinical stability for three consecutive months.
• Vascular endothelial growth factor (VEGF) levels were measured before and after treatment.

Main Results:

• Five out of 16 infants (31.2%) responded to propranolol at 1 mg/kg/day.
• The remaining 11 infants required a dose of 2 mg/kg/day for a clinical response.
• Treatment significantly decreased VEGF levels (P = 0.016).

Conclusions:

• Initiating propranolol treatment at 0.5 mg/kg/day for two days, followed by 1 mg/kg/day for one month, is a recommended approach.
• If no reduction in hemangioma size is observed after one month, the dose should be increased to 2 mg/kg/day.
• This titration strategy allows for effective treatment while monitoring patient response and minimizing potential side effects.